Real-Life Treatment of Metastatic Colorectal Cancer with Regorafenib: A Single-Centre Review
Joanna Gotfrit(Ottawa Hospital), Rachel Goodwin(University of Ottawa), Shelly Sud(Ottawa Hospital), C. Cripps(Canadian Partnership Against Cancer), Tina Hsu(University of Ottawa), Timothy R. Asmis(Ottawa Hospital), Rakesh Goel(Ottawa Hospital), Michael M. Vickers(Ottawa Hospital), Derek J. Jonker(University of Ottawa)
Cited by 12
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
|Nature Reviews Clinical Oncology|2020|365
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
|European Journal of Cancer|2015|337